S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
MarketBeat All Access New Year's Sale - Just $1.00 (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
MarketBeat All Access New Year's Sale - Just $1.00 (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
MarketBeat All Access New Year's Sale - Just $1.00 (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
MarketBeat All Access New Year's Sale - Just $1.00 (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
MarketBeat All Access New Year's Sale - Just $1.00 (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
MarketBeat All Access New Year's Sale - Just $1.00 (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
MarketBeat All Access New Year's Sale - Just $1.00 (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
MarketBeat All Access New Year's Sale - Just $1.00 (Ad)
Most-Upgraded StocksMost-Upgraded
NASDAQ:AMGN

Amgen (AMGN) Stock Price, News & Analysis

$288.02
-0.44 (-0.15%)
(As of 12/29/2023 ET)
Compare
Today's Range
$286.39
▼
$288.49
50-Day Range
$255.70
▼
$288.46
52-Week Range
$211.71
▼
$289.04
Volume
1.77 million shs
Average Volume
2.39 million shs
Market Capitalization
$154.14 billion
P/E Ratio
20.47
Dividend Yield
2.96%
Price Target
$285.71
Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Amgen MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.52 Rating Score
Upside/​Downside
0.8% Downside
$285.71 Price Target
Short Interest
Healthy
1.70% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.42
Upright™ Environmental Score
News Sentiment
0.85mentions of Amgen in the last 14 days
Based on 23 Articles This Week
Insider Trading
Selling Shares
$3.30 M Sold Last Quarter
Proj. Earnings Growth
6.44%
From $18.63 to $19.83 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.74 out of 5 stars

Medical Sector

47th out of 950 stocks

Biological Products, Except Diagnostic Industry

7th out of 158 stocks

See Top Rated MarketRank™ Stocks Here

AMGN stock logo

About Amgen Stock (NASDAQ:AMGN)

Amgen Inc. is a multinational biopharmaceutical company headquartered in Thousand Oaks, California. Established in 1980 by William Bowes from Cetus Corporation and Winston Salser from UCLA, Amgen is now one of the world's largest independent biotechnology companies, with over 24,000 employees worldwide. The company's primary focus is on molecular biology and biochemistry, intending to provide healthcare solutions based on recombinant DNA technology.

Neulasta, one of Amgen's most prominent selling product lines, is used to prevent infections in patients undergoing cancer chemotherapy. Enbrel is another famous selling product line for Amgen, used in the treatment of rheumatoid arthritis and other autoimmune diseases. The company's other products have various applications in treating cancer, anemia, osteoporosis and other conditions.

Amgen has a rich history of strong leadership, with the appointment of several successful CEOs since its inception. Robert A. Bradway is the current CEO and was brought to Amgen in May 2012 following his predecessor's retirement. Bradway has led the company to new heights with strategic acquisitions and partnerships.

Amgen has made at least five major corporate acquisitions. In 2019, the company announced it would acquire Nuevolution AB and the Otezla drug program from Celgene and a 20.5% stake in the Beijing-based BeiGene for $2.7 billion. These acquisitions have strengthened Amgen's drug pipeline and provided new revenue streams for the company. In March 2021, Amgen announced its plans to acquire Five Prime Therapeutics and its lead research drug candidate, bemarituzumab, for $1.9 billion. It also agreed to acquire Rodeo Therapeutics for up to $720 million. These acquisitions are part of the company's ongoing efforts to expand its drug pipeline and bring new treatments to patients.

In 2012, Amgen faced legal issues when it pleaded guilty and agreed to pay $150 million in criminal penalties and $612 million in damages to resolve 11 related whistleblower complaints. Amgen has also faced criticism for lobbying for a two-year extension on sales of drugs, including Sensipar, without government controls, which will cost taxpayers an estimated $500 million. However, the company remains committed to providing innovative and effective healthcare solutions for patients.

Amgen's success can be attributed to its commitment to innovation, strategic acquisitions, strong partnerships and top-end leadership. The company's impressive portfolio of products and its commitment to the community has solidified Amgen's position as a leader in biopharmaceuticals.

AMGN Stock Price History

AMGN Stock News Headlines

December 7, 2023 | marketbeat.com
Is Amazon a blue chip stock? (AMGN)
Is Amazon a blue chip stock or does it fit into a different category? Learn more about Amazon.com Inc. and how to categorize it with MarketBeat.
December 29, 2023 | finance.yahoo.com
Amgen (AMGN) Stock Moves -0.15%: What You Should Know
December 31, 2023 | Behind the Markets (Ad)
New Year's Sale: Get 12 Months of Stock Picks for $9.00
Gear up for what's happening in the stock market in 2024. Our friends at Behind the Markets are offering an opportunity that is simply too good to pass up - 12-months of their best stock ideas for just $9.00. Don't sleep on this.
December 29, 2023 | finance.yahoo.com
Can Amgen's Price Strength Continue Into 2024?
December 29, 2023 | finance.yahoo.com
Amgen Inc: An Exploration into Its Intrinsic Value
December 29, 2023 | finance.yahoo.com
Is Amgen Inc. (NASDAQ:AMGN) Trading At A 40% Discount?
December 28, 2023 | benzinga.com
Amgen's Options: A Look at What the Big Money is Thinking
December 28, 2023 | finance.yahoo.com
Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca Onbody
December 31, 2023 | MarketBeat Internal (Ad)
Claim Your $300 MarketBeat Account Credit
Click the link below to claim your $300.00 account credit toward MarketBeat All Access. Pay just $99.00 for your 2024 MarketBeat All Access subscription (normally $399.00)
December 28, 2023 | americanbankingnews.com
Amgen Inc. (NASDAQ:AMGN) Receives Consensus Recommendation of "Moderate Buy" from Analysts
December 27, 2023 | msn.com
LegoChem signs antibody deal with Amgen worth up to $1.25B
December 26, 2023 | finance.yahoo.com
FDA Wants Another Amgen Study on Lumakras
December 26, 2023 | markets.businessinsider.com
Amgen Says FDA Completes Review Of SNDA Seeking Full Approval For LUMAKRAS
December 26, 2023 | msn.com
Amgen says FDA declined full approval for lung cancer drug Lumakras
December 26, 2023 | msn.com
Full Approval For Amgen's Flagship Cancer Drug Lumakras Pushed For Around Four Years
December 26, 2023 | finance.yahoo.com
Midday Movers: Intel's Israel Deal, Bristol-Myers Squibb Buys RayzeBio
December 26, 2023 | finance.yahoo.com
AMGEN PROVIDES REGULATORY UPDATE ON STATUS OF LUMAKRAS® (SOTORASIB)
December 26, 2023 | finance.yahoo.com
UPDATE 1-US FDA turns down Amgen lung cancer drug Lumakras for full approval
December 23, 2023 | ca.finance.yahoo.com
AMGN Dec 2023 252.500 put
December 22, 2023 | msn.com
Walgreens Boots, Amgen share gains contribute to Dow's 100-point jump
December 22, 2023 | nasdaq.com
AMGN Factor-Based Stock Analysis
December 22, 2023 | americanbankingnews.com
Amgen (NASDAQ:AMGN) Upgraded to "Buy" at Daiwa Capital Markets
December 21, 2023 | msn.com
Daiwa Capital Upgrades Amgen (AMGN)
December 21, 2023 | benzinga.com
Spotlight on Amgen: Analyzing the Surge in Options Activity
December 19, 2023 | msn.com
BMO Capital Upgrades Amgen (AMGN)
December 19, 2023 | msn.com
Amgen Provides Exposure To Obesity Drug At A Reasonable Price, Says Bullish Analyst
December 19, 2023 | msn.com
Dow's nearly 200-point rally highlighted by gains for Walgreens Boots, Amgen stocks
See More Headlines
Receive AMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/31/2023
Ex-Dividend for 12/8 Dividend
11/16/2023
Dividend Payable
12/08/2023
Today
12/31/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
1/30/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:AMGN
CUSIP
03116210
CIK
318154
Web
www.amgen.com
Phone
(805) 447-1000
Fax
805-447-1010
Employees
25,200
Year Founded
1980

Price Target and Rating

Average Stock Price Target
$285.71
High Stock Price Target
$326.00
Low Stock Price Target
$200.00
Potential Upside/Downside
-0.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.52
Research Coverage
21 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$14.07
Trailing P/E Ratio
20.47
Forward P/E Ratio
15.46
P/E Growth
2.75
Net Income
$6.55 billion
Net Margins
28.20%
Pretax Margin
32.61%
Return on Equity
165.37%
Return on Assets
11.59%

Debt

Debt-to-Equity Ratio
7.71
Current Ratio
2.86
Quick Ratio
2.56

Sales & Book Value

Annual Sales
$26.32 billion
Price / Sales
5.86
Cash Flow
$24.35 per share
Price / Cash Flow
11.83
Book Value
$6.86 per share
Price / Book
41.99

Miscellaneous

Outstanding Shares
535,180,000
Free Float
532,716,000
Market Cap
$154.14 billion
Optionable
Optionable
Beta
0.58

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report














AMGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Amgen stock right now?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 2 sell ratings, 6 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AMGN shares.
View AMGN analyst ratings or view top-rated stocks.

What is Amgen's stock price target for 2024?

21 Wall Street research analysts have issued 1 year target prices for Amgen's stock. Their AMGN share price targets range from $200.00 to $326.00. On average, they expect the company's stock price to reach $285.71 in the next twelve months. This suggests that the stock has a possible downside of 0.8%.
View analysts price targets for AMGN or view top-rated stocks among Wall Street analysts.

How have AMGN shares performed in 2023?

Amgen's stock was trading at $262.64 at the beginning of the year. Since then, AMGN stock has increased by 9.7% and is now trading at $288.02.
View the best growth stocks for 2023 here.

When is Amgen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, January 30th 2024.
View our AMGN earnings forecast.

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) posted its quarterly earnings data on Tuesday, October, 31st. The medical research company reported $4.96 earnings per share for the quarter, topping analysts' consensus estimates of $4.65 by $0.31. The medical research company earned $6.90 billion during the quarter, compared to the consensus estimate of $6.92 billion. Amgen had a net margin of 28.20% and a trailing twelve-month return on equity of 165.37%. Amgen's revenue was up 3.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $4.70 earnings per share.
Read the conference call transcript.

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen announced a quarterly dividend on Tuesday, December 12th. Investors of record on Friday, February 16th will be paid a dividend of $2.25 per share on Thursday, March 7th. This represents a $9.00 annualized dividend and a yield of 3.12%. The ex-dividend date is Thursday, February 15th. This is a boost from the stock's previous quarterly dividend of $2.13.
Read our dividend analysis for AMGN.

Is Amgen a good dividend stock?

Amgen (NASDAQ:AMGN) pays an annual dividend of $8.52 per share and currently has a dividend yield of 2.96%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 60.55%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AMGN will have a dividend payout ratio of 42.97% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for AMGN.

What ETFs hold Amgen's stock?

ETFs with the largest weight of Amgen (NASDAQ:AMGN) stock in their portfolio include Timothy Plan Market Neutral ETF (TPMN), VanEck Biotech ETF (BBH), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), ProShares Ultra Nasdaq Biotechnology (BIB), Invesco Pharmaceuticals ETF (PJP), FT Cboe Vest DJIA Dogs 10 Target Income ETF (DOGG) and Invesco Dow Jones Industrial Average Dividend ETF (DJD).

What guidance has Amgen issued on next quarter's earnings?

Amgen issued an update on its FY23 earnings guidance on Tuesday, October, 31st. The company provided earnings per share guidance of $18.20-$18.80 for the period, compared to the consensus earnings per share estimate of $18.36. The company issued revenue guidance of $28.0-$28.4 billion, compared to the consensus revenue estimate of $27.57 billion.

What is Robert A. Bradway's approval rating as Amgen's CEO?

1,239 employees have rated Amgen Chief Executive Officer Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among the company's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 81.0% of employees surveyed would recommend working at Amgen to a friend.

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and Home Depot (HD).

How do I buy shares of Amgen?

Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Amgen have any subsidiaries?
The following companies are subsidiares of Amgen: Abgenix, Alantos Pharmaceuticals, Amgen Canada Inc., Amgen Europe GmbH, Amgen Fremont Inc., Amgen Global Finance B.V., Amgen GmbH Germany, Amgen Ilaç Ticaret Limited Şirketi, Amgen K-A Inc., Amgen Manufacturing Limited, Amgen Research Munich GmbH, Amgen Rockville Inc., Amgen S.A., Amgen S.A.S., Amgen S.p.A., Amgen SF LLC, Amgen Singapore Manufacturing Pte. Ltd., Amgen Technology Ireland Unlimited Company, Amgen Technology Limited, Amgen USA Inc., Amgen Worldwide Holdings B.V., Avidia, Bergamo, BioVex, BioVex Inc., Catherex, Catherex, DeCODE Genetics, Dezima Pharma, Filgrastim and Pegfilgrastim, Five Prime Therapeutics, Five Prime Therapeutics Inc., Gensenta İlaç Sanayi ve Ticaret Anonim Şirketi, Ilypsa, Immunex, Immunex Corporation, Immunex Rhode Island Corporation, KAI Pharmaceuticals, KAI Pharmaceuticals Inc., Kinetix Pharmaceuticals, Laboratorio Quimico Farmaceutico Bergamo, MN Pharmaceuticals, Micromet, Nuevolution, Onyx Pharmaceuticals, Onyx Pharmaceuticals Inc., Onyx Therapeutics Inc., Otezla, Rodeo Therapeutics, Saga Investments Coöperatief U.A., Synergen, TeneoBio, TeneoBio Inc., Tularik, deCODE Genetics ehf, and llypsa Inc..
Read More
This page (NASDAQ:AMGN) was last updated on 12/31/2023 by MarketBeat.com Staff

My Account -